泊沙康唑与急性髓系白血病的真菌预防

Abstract
Figure/Table
References
Related Citation (5)

[1] Cornely O A,Maertens J,Winston D J,et al.Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia[J] .N Engl J Med,2007,356(4):348-359.
[2] Walsh T J,Raad I,Patterson T F,et al.Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy:an externally controlled trial[J] .Clin Infect Dis,2007,44(1):2-12.
[3] Gomes M Z,Mulanovich V E,Jiang Y,et al.Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center,2009 to 2011[J] .Antimicrob Agents Chemother,2014,58(2):865-873.
[4] D ring M,Eikemeier M,Cabanillas Stanchi K M,et al.Antifungal prophylaxis with posaconazole vs.fluconazole or itraconazole in pediatric patients with neutropenia[J] .Eur J Clin Microbiol Infect Dis,2015,34(6):1189-1200.
[5] Caira M,Candoni A,Verga L,et al.Pre-chemotherapy risk factors for invasive fungal diseases:prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)[J] .Haematologica,2015,100(2):284-292.
[6] Wingard J R,Ribaud P,Schlamm H T,et al.Changes in causes of death over time after treatment for invasive aspergillosis[J] . Cancer,2008,112(10):2309-2312.
[7] Rogers T R,Slavin M A,Donnelly J P.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?[J] .Br J Haematol,2011,153(6):681-97.
[8] Caira M,Mancinelli M,Leone G,et al.Invasive aspergillosis in acute leukemias:old and new risk factors andepidemiological trends[J] .Med Mycol,2011,49 (Suppl 1):S13-16.
[9] Busca A,Lessi F,Verqa L,et al.SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy[J] .Leuk Lymphoma,2017,58(12):2859-2864.
[10] Shen Y,Huang X J,Wang J X,et al.Posaconazole vs.fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized,open-label study[J] .Int J Clin Pharmacol Ther,2013,51(9):738-745.
[11] Zoller E,Valente C,Baker K,et al.Development, clinical utility, and place in therapy of posaconazole forprevention and treatment of invasive fungal infections[J] .Drug Des Devel Ther,2010,4(4):299-311.
[12] Candoni A,Caira M,Cesaro S,et al.Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients:the SEIFEM real-life combo study[J] .Mycoses,2014,57(6):342-350.
[13] Tonini J,Thiébaut A,Jourdil J F,et al.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease[J] .Antimicrob Agents Chemother,2012,56(10):5247-5252.
[14] Jang S H,Colangelo P M,Gobburu J V.Exposure-response of posaconazole used for prophylaxis against invasive fungal infections:evaluating the need to adjust doses based on drug concentrations in plasma[J] .Clin Pharmacol Ther,2010,88(1):115-119.
[15] Lerolle N,Raffoux E,Socie G,et al.Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis:a 4-year study[J] .Clin Microbiol Infect,2014,20(11):O952-959.
[16] Leung S,Poulakos M N,Machin J.Posaconazole:An Update of Its Clinical Use[J] .Pharmacy (Basel),2015,3(4):210-268.
[17] Cámara R,Gozalbo I,Jurado M,et al.Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain[J] .Adv Ther,2017,34(9):2104-2119.
[18] Cornely O A,Robertson M N,Haider S,et al.Pharmacokinetics and safety results from the Phase 3 randomized,open-label,study of intravenous posaconazole in patients at risk of invasive fungal disease[J] .J Antimicrob Chemother,2017,72(12):3501.
[19] Yi W M,Schoeppler K E,Jaeger J,et al.Voriconazole and posaconazole therapeutic drug monitoring:a retrospective study[J] .Ann Clin Microbiol Antimicrob,2017,16(1):60.
[20] D ring M,Müller C,Johann P D,et al.Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation[J] .BMC Infect Dis,2012,19(12):263.
[21] Perfect J R,Corcoran G,Pedicone L,et al.Posaconazole safety and efficacy in elderly patients with invasive fungal infections[C] .Boston,42nd.Meeting of the Infectious Diseases Society of America,2004.
[22] Nederlof M,Stoker L J,Egberts T C,et al.Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: Overview and applicability in clinical practice[J] .J Psychopharmacol,2015,29(12):1248-1254.
[23] Michallet M,Sobh M, Morisset S,et al.Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole[J] .Med Mycol,2011,49(7):681-687.

[1]	. [J]. 滨州医学院学报, 2019, 42(2): 149-150.
[2]	. [J]. 滨州医学院学报, 2019, 42(2): 154-155.
[3]	. [J]. 滨州医学院学报, 2019, 42(2): 156-157.
[4]	. [J]. 滨州医学院学报, 2018, 41(6): 476-477.
[5]	. [J]. 滨州医学院学报, 2018, 41(2): 159-161.